A Clinical Trial of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.

Phase 1 Not yet recruiting 36 enrolled Genrix (Shanghai) Biopharmaceutical Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and immunogenicity characteristics of GR2301 injection in healthy adult subjects in China. The Multiple doses will be gradually escalated.

Timeline

Start: 2026-06
Primary completion: 2027-07
Completion: 2027-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GR2301	Monoclonal antibody	—	—

Indications

No indication recorded.